Global Organoid Biobank Market Growth (Status and Outlook) 2025-2031

The global Organoid Biobank market size is predicted to grow from US$ 188 million in 2025 to US$ 538 million in 2031; it is expected to grow at a CAGR of 19.2% from 2025 to 2031.

Organoids refer to three-dimensional tissue structures constructed in vitro through cell engineering, tissue engineering, or stem cell technology based on internal organs.

The organoid biobank market is a growing field that encompasses the collection, storage, and distribution of human organoid models and biological samples required for a variety of medical and biological research. Key drivers of this market include increased demand for medical research, advances in organ transplantation and drug testing, developments in biotechnology, and the rise of personalized medicine. These biobanks provide researchers and pharmaceutical companies with important resources for disease research, drug screening, and personalized medicine, and therefore have huge potential and market opportunities in the fields of medicine and life sciences.

ReportPrime's newest research report, the “Organoid Biobank Industry Forecast” looks at past sales and reviews total world Organoid Biobank sales in 2024, providing a comprehensive analysis by region and market sector of projected Organoid Biobank sales for 2025 through 2031. With Organoid Biobank sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Organoid Biobank industry.

This Insight Report provides a comprehensive analysis of the global Organoid Biobank landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest developments, and M&A activity. This report also analyses the strategies of leading global companies with a focus on Organoid Biobank portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Organoid Biobank market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Organoid Biobank and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Organoid Biobank.

This report presents a comprehensive overview, market shares, and growth opportunities of the Organoid Biobank market by product type, application, key players, and key regions and countries.

Segmentation by Type:

• Tissue Derived Organoids
• Pluripotent Stem Cell-derived Organoids

Segmentation by Application:

• Biopharmaceutical Companies
• Contract Research Organizations
• Academics and Research Institutes

Market by Region:

• Americas
• APAC
• Europe
• Middle East & Africa

Company's Coverage:

• FRANKFURT CANCER INSTITUTE
• Merck
• Crown Bioscience
• HUB Organoids
• Cancer Research UK Convergence Science Centre
• Thermo Fisher Scientific
• Corning
• STEMCELL Technologies
• Lonza
• Prellis Biologics
• Amsbio
• Cellesce
• DefiniGEN
• 3Dnamics Inc.
• Organoid Therapeutics
• InSphero
• AIVITA Biomedical
• JangoBio

Key Questions Addressed in this Report: